Last reviewed · How we verify
Tozinameran (BNT162b2) (tozinameran-bnt162b2)
Tozinameran (BNT162b2) is an mRNA vaccine that instructs cells to produce the SARS-CoV-2 spike protein, triggering an immune response.
At a glance
| Generic name | tozinameran-bnt162b2 |
|---|---|
| Sponsor | Pfizer Inc. |
| Therapeutic area | Other |
| Phase | FDA-approved |
Mechanism of action
Tozinameran delivers genetic instructions to cells, which then produce the coronavirus spike protein. This prompts the body to develop antibodies and immune memory against the virus, protecting against COVID-19.
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tozinameran (BNT162b2) CI brief — competitive landscape report
- Tozinameran (BNT162b2) updates RSS · CI watch RSS
- Pfizer Inc. portfolio CI